Desmopressin (1-deamino-8-d-arginine vasopressin, DDAVP) releases endothelial von Willebrand factor and factor VIII, enhances platelet adherence and platelet aggregate growth on human artery subendothelia and is the first choice in the treatment of bleeding in patients with von Willebrand disease, a disorder which occurs in roughly 1 in 100 patients [829]. The gene discussed is VWF; the disease is platelet-type von Willebrand disease.